secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001437749-24-003357
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Joshua Boger, founder of Vertex, appointed Chair of CervoMed Board; RewinD-LB trial on track
--------------------------------------------------------------------------------

- Joshua Boger, Ph.D., former CEO and founder of Vertex Pharmaceuticals, appointed as director and Chair of CervoMed Board effective Feb 7, 2024.
- CervoMed expects to fully enroll RewinD-LB Phase 2b trial in 1H 2024; topline data for neflamapimod in DLB expected in 2H 2024.
- Boger beneficially owns 561,309 shares (~9.90% of CRVO) and pre-funded warrants for 495,995 shares.
- Dr. Sylvie Gregoire steps down as Chair but remains on Board.
- Boger will receive 10,000 stock option grant and standard non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/0001437749-24-003357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/crvo20240205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-003357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer